SCHEMBL3965290

SCHEMBL3965290

CCCCCCCCN(Cc1ccc(F)cc1F)C(=O)COc1ccc(C(CC)[C@H](OCC)C(=O)O)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.39
HSD17B10 Q99714 1/20 0.39
HTR2A P28223 3/20 0.39
FAAH O00519 1/20 0.38
PPARG P37231 2/20 0.36
PPARA Q07869 2/20 0.36
MAOB P27338 1/20 0.36
LTB4R2 Q9NPC1 1/20 0.35
FFAR1 O14842 1/20 0.35
TRPM8 Q7Z2W7 1/20 0.35
SOAT1 P35610 1/20 0.35
MME P08473 1/20 0.34
ACE P12821 1/20 0.34
CPA1 P15085 1/20 0.34
ACE2 Q9BYF1 1/20 0.34
PSEN1 P49768 1/20 0.34
PSEN2 P49810 1/20 0.34
APH1B Q8WW43 1/20 0.34
NCSTN Q92542 1/20 0.34
APH1A Q96BI3 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3964921 1.00 USP2 (0.39) USP2HSD17B10HTR2AFAAHPPARG
SCHEMBL3963237 1.00 USP2 (0.39) USP2HSD17B10HTR2AFAAHPPARG
SCHEMBL3960457 0.87 FFAR1 (0.49) USP2HSD17B10HTR2AFAAHPPARG
SCHEMBL3956932 0.86 MAPT (0.39) HTR2APPARAMAOBFFAR1TRPM8
SCHEMBL3960796 0.83 TRPM8 (0.48) USP2HSD17B10LTB4R2TRPM8
SCHEMBL3963764 0.83 PPARA (0.47) HTR2APPARGPPARA
SCHEMBL3965062 0.83 PPARA (0.47) HTR2APPARGPPARA
SCHEMBL3962800 0.83 PPARA (0.47) HTR2APPARGPPARA
SCHEMBL4073462 0.83 PPARA (0.47) HTR2APPARGPPARA
SCHEMBL3959940 0.83 FFAR1 (0.39) HTR2AMAOBFFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7488844-B2 Therapeutic agents ASTRAZENECA AB (SE) 2009-02-10 US disclosed
US-20050282822-A1 Therapeutic agents ASTRAZENECA AB (SE) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282822-A1 Therapeutic agents GPR119, LIPC, PNLIP USP2 4267/4885HSD17B10 193/4885HTR2A 4493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.